China Medical University

Academia Sinica

Industrial Technology Research Institute

University of North Carolina at Chapel Hill

Neuralstem, Inc.

China Medical University Hospital

Stemcyte, Inc.

Woei-Cherng Shyu

Chang-Hai Tsai

Chen-Huan Lin

Wei Lee

Shinn-Zong Lin

Chung-Y Hsu

Hung Li

Chia-Hung Hsieh

Long-Bin Jeng

San-Yuan Chen

Hsiao-Jung Wang

Sheng-Chu Kuo

Yu-Ting Huang

Mean-Jue Tung

Der-Yang Cho

Yi-Shan Lin

Li-Kou Chen

Kuo-Hsiung Lee

Che-Ming Teng

Hsin-Hsin Shen

Yang-Chang Wu

Karl K Johe

Shiow-Lin Pan

Tian-Shung Wu

Wei-Lin Yu

Dah-Ching Ding

Ling-Chu Chang

Hsin-Yi Hung

Min-Tsang Hsieh

Xiaoming Yang

Shih-Ping Liu

Hsiang-Ming Huang

Chih-Sheng Chiang

Shin-Zong Lin

Demeral David Liu

Chien-Lin Chen

Masuo Goto

Chung Y Hsu

Zhi-Jun Zhang

Chih-Ya Wang

Yu-Jung Lin

Yu Zhao

Yu-Chian Chen

Chun-Wei Chiang

Keduo Qian

Ying-Qian Liu

Yong-Long Zhao

Liu Yang

Mei-Juan Wang

A method for enhancing an expression of insulin like growth factor 1 receptor in an umbilical cord mesenchymal stem cell is provided. The method includes culturing the umbilical cord mesenchymal stem cell expressing insulin-like growth factor 1 receptor in a medium containing platelet-derived growth factor BB (PDGF-BB) to enhance the expression of insulin like growth factor 1 receptor in the umbilical cord mesenchymal stem cell.

Method for enhancing expression of insulin like growth factor 1 receptor in umbilical cord mesenchymal stem cell expressing IGF1R and method for obtaining multipotent umbilical cord mesenchymal stem cell

The present disclosure provides an iPSC cell derived from a somatic cell comprising a Cbx family gene and the applications thereof. Also provided are methods for generating the somatic cells that have potential to become induced pluripotent stem (iPS) cells (iPS cells) without oncogenic properties, and methods for generating iPS cells from the population of cells, which may then be used for transplantation and for cellular differentiation and interaction.

Induced pluripotent stem cells (IPSCS) and applications thereof

A method for enhancing an expression of insulin like growth factor 1 receptor in a mesenchymal stem cell is provided. The method includes culturing the mesenchymal stem cell expressing insulin-like growth factor 1 receptor in a medium containing platelet-derived growth factor BB (PDGF-BB) to enhance the expression of insulin like growth factor 1 receptor in the mesenchymal stem cell.

Method for enhancing expression of insulin like growth factor 1 receptor in mesenchymal stem cell, method for obtaining mesenchymal stem cell, and method for treating brain tissue damage

The present disclosure provides an engineered stem cell, comprising a vector comprising a polynucleotide comprising a nucleic acid sequence of suicide gene, a nucleic acid sequence of immune checkpoint gene and a natural cytotoxicity triggering receptor or a TNF-related apoptosis-inducing ligand, wherein the stem cell is a tumor-targeting cell. The present disclosure also provides a method for treating a cancer or enhancing intratumor immunity or enhancing immunity in tumor microenvironment in a subject, comprising administering an effective amount of the engineered stem cell of the present disclosure to the subject.

Engineering stem cells for cancer therapy

The invention relates to the treatment of chronic stroke, traumatic brain injury, and neurodegenerative disorders using umbilical cord blood cells.

Treatment of brain damage using umbilical cord blood cells

A method for treating a multiple sclerosis is provided. The method includes administering a composition containing a plurality of mesenchymal stem cells to a subject in need for a treatment of the multiple sclerosis, in which each of the mesenchymal stem cells expresses insulin-like growth factor 1 receptors.

Method for treating multiple sclerosis

A method for obtaining a plurality of pluripotent adult olfactory stem cells (APOSCs) includes isolating the APOSCs, culturing the isolated APOSCs in a sphere culture medium, and collecting the cultured APOSCs that express Bmi-1 (B-lymphoma moloney murine leukemia virus insertion region-1), Oct-4 (Octamer-binding transcription factor 4), Sox-2 (Sex-determining region Y (SRY)-box 2), Nanog, SSEA-4 (Stage-specific embryonic antigen-4), ki67, c-Myc, KLF-4 (Kruppel Like Factor 4), K14 (Cytokeratin 14) and ICAM-1 (Intercellular Adhesion Molecule 1).

Methods for obtaining pluripotent adult olfactory stem cells from an olfactory mucosa tissue

An immunomagnetic nanocapsule includes a core, a shell and an outer layer. The shell is formed by a complex, and the complex is fabricated by a combination of fucoidan, oxidized dextran, and a plurality of superparamagnetic iron oxide nanoparticles via a hydrophobic interaction. The core is encapsulated in the shell. The outer layer includes at least one antibody immobilized to outside of the shell to form the outer layer, wherein the antibody is an immune checkpoint inhibitor and/or a T cell expansion antibody.

Immunomagnetic nanocapsule and kit for treating cancer

A composition including adult pluripotent olfactory stem cells is provided. The adult pluripotent olfactory stem cells are obtained by culturing a cell mixture from an olfactory tissue of a mammal in media containing growth factors and then isolating cells which express B-lymphoma moloney murine leukemia virus insertion region-1 (Bmi-1).

Methods for treating a brain tissue damage by cultured adult pluripotent olfactory stem cells

A method for enhancing an insulin like growth factorreceptor expression of a mesenchymal stem cell is provided. The method includes culturing a plurality of mesenchymal stem cells expressing insulin-like growth factorreceptors in media containing human cord blood serum to enhance the insulin like growth factorreceptor expression of the mesenchymal stem cells.

Method for enhancing insulin like growth factor 1 receptor expression of mesenchymal stem cell, method for isolating mesenchymal stem cell, and use of mesenchymal stem cell

The present disclosure relates to a bicyclic compound, a pharmaceutical composition thereof, and its novel use. More particularly, the present disclosure relates to the bicyclic compound according to Formula I or Formula II, the pharmaceutical composition for treating a stroke, and the use of the bicyclic compound treating the stroke.

Bicyclic compound and pharmaceutical composition thereof for treating stroke and use thereof

The present invention is related to novel 20-sulfonylamidine derivatives of camptothecin (1), method of synthesizing the same, and use thereof as an antitumor agent, for examples an antitumor agent for treating nasopharyngeal, lung, breast or prostate cancer.

[object Object]

The present disclosure provides methods for the treatment of neurological diseases/disorders using neural stem cells (NSCs) obtained from a spinal cord tissue. The methods may include the use of a NSC population to treat a neurological disease/disorder of the brain. Such methods may include introducing exogenously cultured and expanded NSCs into the brain, which differentiate into neurons capable of integrating in vivo into the brain tissue in a sufficient manner to ameliorate the symptoms associated with the neurological disease/disorder.

Methods for treating and/or reversing neurodegenerative diseases and/or disorders

A magnetic separation unit is provided, including a first member made of non-magnetic materials comprising a trench extending within the first member and a second member made of magnetic materials including a protrusion portion protruding over a surface of the second member, wherein the first member connects the second member such that the trench functions as a fluid channel formed between the first and second members, and the protrusion portion of the second member is contained by the trench of the first member.

Magnetic separation unit, magnetic separation device and method for separating magnetic substance in bio-samples

A magnetic separation device is provided, including a first magnetic field unit and a first separation unit disposed at a side of the first magnetic field unit. The first magnetic field unit includes a first magnetic yoke having opposite first and second surfaces, and a plurality of first magnets respectively disposed over the first and second surfaces, wherein the same magnetic poles of the plurality of first magnets face the first magnetic yoke. The first separation unit includes a body made of non-magnetic materials and a continuous piping disposed in the body, including at least one first section and at least one second section, wherein at least one second section is perpendicular to at least one first section, and at least one second section is adjacent to, and in parallel to a side of the first magnetic yoke not in contact with the plurality of first magnets.

Magnetic separation device and method for separating magnetic substance in bio-samples

Growing community of inventors

Taipei, Taiwan

Woei-Cherng Shyu